ORPHA:390
Histoplasmosis
Also known as: Darling disease
Clinical definition (Orphanet)
A rare mycosis characterized by granulomatous inflammation primarily of the lung after inhalation of spores of Histoplasma capsulatum. The severity of clinical disease depends on the immune status of the individual and the size of the inoculum. In immunocompetent persons, the infection usually takes a self-limiting and asymptomatic or relatively mild, flu-like course. In immunocompromised patients, it can become and disseminated, involving multiple organs and presenting with fever, pneumonia, , skin infiltrates, and endocarditis, among others.
Is anyone studying this?
23,860
23,860 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
23,860 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
10,121 in the last 10 years · low confidence
Is a treatment being tested?
24
trials for this specific condition
24 interventional trials matched this specific condition name; 3 currently recruiting in our sample.
Data as of 26 July 2026
24 interventional trials — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 92.4th percentile).
low confidence · 92.4th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
1,228
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Pasqualotto AC8 papers · 2026
Department of Clinical Medicine, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Brazil.
Papers in Europe PMC - 02Bahr NC6 papers · 2026
Division of Infectious Diseases, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Papers in Europe PMC - 03Françoise U6 papers · 2026
Centre d'Investigation Clinique Antilles Guyane, Inserm CIC 1424, Centre Hospitalier de Cayenne, Cayenne, Guyane française.
Papers in Europe PMC - 04Kauffman CA6 papers · 2026
Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Papers in Europe PMC - 05Nacher M5 papers · 2026
Centre d'Investigation Clinique Antilles Guyane, Inserm CIC 1424, Centre Hospitalier de Cayenne, Cayenne, Guyane française.
Papers in Europe PMC - 06Spec A5 papers · 2026
Division of Infectious Diseases, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Papers in Europe PMC - 07Adenis A4 papers · 2026
CIC INSERM 1424, Centre Hospitalier de Cayenne, French Guiana, France.
Papers in Europe PMC - 08Benedict K4 papers · 2026
Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Papers in Europe PMC - 09Damasceno LS4 papers · 2026
São José Hospital of Infectious Diseases, Fortaleza, CE 60455-610, Brazil.
Papers in Europe PMC - 10Saccente M4 papers · 2026
Department of Internal Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
24 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07695298·A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
- NCT05814432·Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
- NCT07261150·Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Histoplasmosis" OR "Darling disease" OR "Histoplasma caused disease or disorder" OR "Histoplasma disease or disorder" OR "Histoplasma infectious disease"
MeSH descriptor terms unioned into the query: Histoplasmosis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Histoplasmosis" OR "Darling disease" OR "Histoplasma infectious disease"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 24 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Cross-references (from Mondo): MESH:D006660 UMLS:C0019655 NCIT:C77201
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (23860) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity